Epigenetic biomarkers of prostate cancer - looking beyond PSA

7^th International Conference and Expo on Molecular & Cancer Biomarkers

September 15-16, 2016 Berlin, Germany

Mithu Banerjee

Command Hospital, Northern Command C/o 56 APO, India

Posters & Accepted Abstracts: J Mol Biomark Diagn

Abstract :

Background: Prostate cancer is the second most common cancer among men worldwide. Presently, the most common noninvasive mode of screening, prognostication and management is estimation of serum PSA. However, the sensitivity of PSA is 42.8 % and specificity is 41.1%. Therefore, a rigorous search for newer biomarkers for early detection of prostate cancer have been warranted. Methods: Sixteen primary matched tumor and serum were analyzed by fluorogenic quantitative methylation specific PCR (QMSP) to determine analytical and clinical sensitivity of the genes tested (SSBP2, MCAM, ER�±, ER�², APC, CCND2, MGMT, GSTP1, p16 and RAR�²2). Additionally, same QMSP assay was employed in serum samples from eighty four cases of prostate cancer, thirty controls and seven cases diagnosed as high grade Prostatic Intraepithelial Neoplasia (HGPIN). ROC curves were plotted for each of the genes to calculate sensitivity and specificity. Results: The sensitivity and specificity of hypermethylation of MCAM was 65% and 62% respectively which is an improvement from the sensitivity and specificity of PSA. When a panel approach was taken, a combination of MCAM, p16 and ER alpha increased the sensitivity to 70.23 and the specificity remained the same. Conclusion: Although need to be validated in a larger cohort, promoter DNA methylation of MCAM, p16 and ER alpha have a potential to be utilized as biomarkers for prostate cancer as their sensitivity and specificity is better than serum PSA in our cohort of samples. After validation, our findings may reduce the numbers of unwarranted prostate biopsies which cause morbidity to patients.

Biography :

Email: mithu.banerjee.3@gmail.com